SCHEMBL16571915

SCHEMBL16571915

O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CC[C@@H](NC2CCCC2)C1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 20/20 0.71
▸ PARP2 Q9UGN5 2/20 0.69
▸ PRAP1 Q96NZ9 1/20 0.68
▸ PARP3 Q9Y6F1 2/20 0.68
▸ TNKS O95271 1/20 0.68
▸ ADORA1 P30542 1/20 0.68
▸ CDK6 Q00534 1/20 0.68
▸ PDE3A Q14432 1/20 0.68
▸ PARP6 Q2NL67 1/20 0.68
▸ PARP15 Q460N3 1/20 0.68
▸ PARP14 Q460N5 1/20 0.68
▸ PARP10 Q53GL7 1/20 0.68
▸ TIPARP Q7Z3E1 1/20 0.68
▸ PARP8 Q8N3A8 1/20 0.68
▸ PARP16 Q8N5Y8 1/20 0.68
▸ PARP12 Q9H0J9 1/20 0.68
▸ TNKS2 Q9H2K2 1/20 0.68
▸ PARP11 Q9NR21 1/20 0.68
▸ PARP4 Q9UKK3 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30436925 1.00 PARP1 (0.71) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL30437169 1.00 PARP1 (0.71) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL16571918 1.00 PARP1 (0.71) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL16571527 0.98 PARP1 (0.71) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL30437021 0.98 PARP1 (0.71) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL16571526 0.98 PARP1 (0.71) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL16571823 0.97 PARP1 (0.73) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL16571825 0.97 PARP1 (0.73) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL30437091 0.97 PARP1 (0.73) PARP1PARP2PRAP1PARP3TNKS
SCHEMBL30436717 0.97 PARP1 (0.73) PARP1PARP2PRAP1PARP3TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030557-B1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF IDIENCE CO LTD (KR) 2023-05-31 — — EP claimed
US-RE49338-E1 Phthalazinone derivatives and manufacturing process thereof IDIENCE CO., LTD. (KR) 2022-12-20 — — US claimed
US-9844550-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-12-19 — — US claimed
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2017-06-29 — — US claimed
US-9682973-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-06-20 — — US claimed
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2016-08-04 — — US claimed
EP-3030557-A1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF Ildong Pharm Co., Ltd. (KR) 2016-06-15 — — EP claimed
WO-2015037939-A1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF ILDONG PHARM CO., LTD. (KR) 2015-03-19 — — WO claimed
EP-3030557-B1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF IDIENCE CO LTD (KR) 2023-05-31 — — EP disclosed
US-RE49338-E1 Phthalazinone derivatives and manufacturing process thereof IDIENCE CO., LTD. (KR) 2022-12-20 — — US disclosed
US-9844550-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-12-19 — — US disclosed
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2017-06-29 — — US disclosed
US-9682973-B2 Phtalazinone derivatives and manufacturing process thereof ILDONG PHARM CO., LTD (KR) 2017-06-20 — — US disclosed
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof IL DONG HOLDINGS CO., LTD (KR) 2016-08-04 — — US disclosed
EP-3030557-A1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF Ildong Pharm Co., Ltd. (KR) 2016-06-15 — — EP disclosed
WO-2015037939-A1 A NOVEL PHTALAZINONE DERIVATIVES AND MANUFACTURING PROCESS THEREOF ILDONG PHARM CO., LTD. (KR) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222003-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof PARP15, PARP10, PARP1 PARP1 3/4885PARP2 12/4885PRAP1 439/4885
US-20170182045-A1 Novel Phtalazinone Derivatives and Manufacturing Process Thereof PARP15, PARP10, NUDT5 PARP1 4/4885PARP2 12/4885PRAP1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback